Rating Change
HC Wainwright & Co. reiterated its Buy rating on Nuvation Bio Inc. (NYSE:NUVB) on November 17, 2026.
HC Wainwright & Co. reiterated its Buy rating on Nuvation Bio Inc.

At publication ·
Nuvation Bio Inc. (NYSE:NUVB) · reiterate
At a glance
HC Wainwright & Co. reiterated its Buy rating on Nuvation Bio Inc. (NYSE:NUVB) on November 17, 2026.
Nuvation Bio Inc. operates in the Healthcare sector. The stock currently trades at $3.92 with a market capitalization of $2.8B.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Nuvation Bio Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 17, 2026 | HC Wainwright & Co. | Buy | N/A |
| Nov 05, 2026 | RBC Capital | Outperform | N/A |
| Sep 30, 2026 | Citigroup | Buy | N/A |
| Sep 16, 2026 | Citizens | Market Outperform | N/A |
| Sep 16, 2026 | Wedbush | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View NUVB Stock Page
A rating of Buy from HC Wainwright & Co. reflects the analyst's outlook on Nuvation Bio Inc. (NYSE:NUVB). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the NUVB forecast page.
Current market data
NYSE · NUVB
$3.78
Down: -$0.12 · -3.08%
Live quote updated
Keep reading